Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras. Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis. Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.

Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology. By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds by fermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow. Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

Based on my 20 years’ experience within quality management and quality assurance, I was increasingly puzzled by the absence of standardization and efficiency in the implementation of regulatory frameworks. Instead of ‘fixing’ compliance for individual customers and isolated projects, I was looking for standardization, scalability and a solution that would be accessible for all. That is the reason why we created MyBlueLabel

Steeper Energy is a world leader in the development of advanced biofuels from low-value biomass, such as residues and wastes from the agriculture and forest industries. Steeper Energy’s Hydrofaction™ produces drop-in renewable fuels with high energy density enabling the heavy transport sector to seamlessly transition to low carbon fuels. With an experienced team of world class talents and strong industrial partnerships, Steeper is a leader in the realization of a low-carbon transport future. Steeper Energy offers a solution to a stated goal by society to reduce carbon emissions. Climate changes caused by utilization of fossil fuels are known to cause global damage. Within transportation carbon emissions keep rising while leaders across the globe have made bold commitments to bring emissions down. Electrification of light vehicles provides part of the solution. However, heavy trucking, marine and aviation cannot be readily electrified, and despite improvements in fuel efficiencies emissions from long distance heavy transport are predicted to go up. The international community is struggling to find solutions and agree that action cannot be delayed. Steeper Energy’s proprietary Hydrofaction process cost effectively converts biomass to renewable transport fuels that can be used in existing infrastructure.

Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a primary focus towards orphan diseases. The company is a leader in the rapidly developing field of individualized cell-based therapies for solid tumors, and is using the ALECSAT platform to generate best-in- class therapeutics to treat cancer with a high unmet medical need.

AdaptVac is a joint-venture between ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders.

From their headquarters in Hørsholm, Zenegy is working towards paving the way for a whole new generation of pay systems. A payroll system, where you make up with the classic wage-setup and instead moves on an open platform of innovation and ease of use.

RhoVac is an immuno-oncology company developing a novel therapeutic cancer vaccine that targets metastatic cancer cells. Overexpression of RhoC protein is a characteristic of most type of metastatic cancer cells. The cancer vaccine product RV001, already in clinical trial, recognises cells with high concentration of RhoC and stimulate the immune system to target them. RhoVac’s concept focuses on eliminating cancer cells having metastatic potential that escape treatment of the parent tumour via other methods. The company is based in Sweden and Denmark and is publicly traded in Swedish stock market. RhoVac is managed and advised by a senior team of executives with extensive expertise built upon years of experience.

Comcores is a provider of IP cores for communication systems and offers customization services in order to integrate these into customer systems. Comcores is a specialist in digital radio systems and help companies succeed in their efforts to realize digital radio systems for wireless communication by delivering IP cores and design services. Comcores is founded by Thomas Gerner Nørgaard in 2014.

immunAware specializes in creating advanced peptide-major histocompatibility complex class I and II monomers and tetramers. Their innovative methods are developed in the experimental immunology laboratory, offering cutting-edge solutions for immune system research.

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras. Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis. Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.

Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology. By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds by fermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow. Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.

ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.

Læsk use fermentation as the key to unlock flavours and reduce sugar. Læsk is the miniproduction of microorganism-fermented soft drinks.

Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology. By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds by fermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow. Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras. Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis. Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.

AdaptVac is a joint-venture between ExpreS2ion Biotech and University of Copenhagen spin-out NextGen Vaccines. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders.

MedTech Careers is an initiative developed by Medicoindustrien – MedTech Denmark – in collaboration with several medical technology companies. The initiative aims to inform students in STEM fields about career opportunities in the medtech industry. It offers a job portal, career events, and educational materials to explain various roles related to devices like CT scanners, insulin pens, and surgical instruments. The initiative addresses the need for workers in the sector by providing information on employment options.

From their headquarters in Hørsholm, Zenegy is working towards paving the way for a whole new generation of pay systems. A payroll system, where you make up with the classic wage-setup and instead moves on an open platform of innovation and ease of use.

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras. Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis. Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.

Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology. By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds by fermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow. Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.

From their headquarters in Hørsholm, Zenegy is working towards paving the way for a whole new generation of pay systems. A payroll system, where you make up with the classic wage-setup and instead moves on an open platform of innovation and ease of use.

IT Confidence A/S specializes in providing internet-based solutions and services. With a focus on enhancing digital infrastructure, the company offers expertise in areas such as HTTPS, Hybrid Cloud, and Identity and Access Management (IAM). IT Confidence A/S aims to support businesses in securing and optimizing their online presence and operations. The company also provides customer support and has developed a tool for domain name analysis, indicating a commitment to comprehensive internet services. With a team of 10 employees, IT Confidence A/S caters to a variety of internet service needs from its base.

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world. Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras. Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis. Their company has grown into an international business with over 500 licenses in more than 30 countries. Their growing network of authorized distributors and partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Their headquarters is located in the Medicon Valley of Denmark, with a branch office in the Netherlands, and a North America office in Broomfield, Colorado.